The Marked Chart Wire · Series of events
Series of events · Eli Lilly
Eli Lilly shares rise ahead of third-quarter earnings
Stock climbed after positive trial data for retatrutide, setting the stage for upcoming quarterly results driven by obesity drugs.
Updated
What happened, in order
Times are Eastern-
Where it began
Trial data boosts stock
Eli Lilly stock climbed 1.89 percent in after-hours trading following favorable Phase 3 data for its diabetes drug retatrutide.
Read the story -
Earnings date set
Eli Lilly is scheduled to release its third-quarter financial results, with performance expected to be driven by its obesity and diabetes medications.
Read the story -
Latest
Estimates raised on sales
Analysts expect Eli Lilly revenue to exceed forecasts due to resilient demand for Zepbound and Mounjaro ahead of the report.
Read the story
How they connect
The company first saw its shares rise after positive trial results for retatrutide. This occurred just before the scheduled release of its third-quarter financial results, where analysts expect strong performance from existing drugs.
What to watch
- Eli Lilly third-quarter earnings release
The stocks in this series
Prices from Before the open · based on Wed close · Opens 9:30 AM ET. Each tile opens the stock's chart and news.
A series is a short summary of connected news, for learning. Not verified and not advice. Check the full stories before you act.